Immunogenicity of synthetic long peptides and the role of formulation and structure for efficacy and toxicity

  • Datum: –13.00
  • Plats: Online seminarium (via https://uu-se.zoom.us/j/63237323527)
  • Föreläsare: Dr. Martin Lord, SweDeliver
  • Webbsida
  • Arrangör: SweDeliver & NextBioForm
  • Kontaktperson: Christel Bergström
  • Seminarium

I dagens SweDeliver & NextBioForm seminarium presenterar Martin Lord sitt arbete inom ramarna för SweDeliver vid Sara Mangsbos forskningsmiljö i immunonkologi vid Uppsala universitet. Välkommen att delta online via https://uu-se.zoom.us/j/63237323527

Abstract: To combat bacterial and viral infections, and as of recent, certain forms of cancer, vaccination has become an instrumental tool for eliciting disease specific adaptive immune responses. One approach is to implement synthetic long peptides (SLPs), which exclusively encompass the immunogenic epitopes derived from one of these proteins, but often also including T and B cell epitopes to evoke a stronger immune stimulation. This project aims to characterize a set of SLPs harboring HLA-specific T cell epitopes in terms of their immunogenicity and how formulation and structure impacts efficacy and toxicity.

Forskarbio: Martin Lord har sin bakgrund inom bioteknik och cancerforskning och tog sin civilingenjörsexamen i molekylär bioteknik vid KTH, samt sin doktorsexamen i tumörbiologi/lymfom vid Karolinska Institutet. Martin Lords nuvarande forskningsfokus är på immunterapi och utveckling av biologiska läkemedel, särskilt för urinblåsecancer, inklusive upptäckt av biomarkörer samt bioinformatik.

Immunogenicity of synthetic long peptides and the role of formulation and structure for efficacy and toxicity